The 2013 revelation of Angelia Jolie’s BRCA status and the U.S. Supreme Court’s ruling invalidating the patentability of the BRCA gene the following month thrust BRCA testing into the limelight. Already recognized in clinical circles as perhaps the most prominent example of how knowledge of genetic variants can be used to reduce disease risk, the high-profile status the BRCA gene garnered in lay media increased public awareness of genetic testing and its potential implications. Given the anniversary of both of these events, DTET examined how BRCA testing has changed over the course of the past year and how the rapidly expanding market will evolve in the coming years. The most immediate implication of the Supreme Court’s unanimous decision against gene patenting in June 2013 was competition for Myraid Genetics (Salt Lake City), which had previously held exclusive testing rights for all BRCA testing in the nation. Not only did other laboratories, such as Ambry Genetics and GeneDx, immediately begin offering a BRCA test, but additional entrants have entered the market throughout the year, including national laboratories LabCorp and Quest Diagnostics. Competition “BRCA testing now has quite a lot of competition,” Amanda Murphy, an analyst with William Blair & Co., tells […]